Clinical evaluation of Cefpodoxime proxetil (CPDX-PR) in the treatment of oral infections.
スポンサーリンク
概要
- 論文の詳細を見る
The clinical efficacy, safety and utility, and also the optimal dose of Cefpodoxime proxetil (CPDX-PR) in the treatment of odontogenic infections such as periodontitis, pericoronitis and osteitis of jaw were evaluated in 12 institutions. CPDX-PR was applied to 228 patients for odontogenic infections and the dosage was divided into two doses. (200 mg/day and 400 mg/day) The following results were obtained.<BR>1) The overall clinical efficacy rate determined according to the standards established by the committee was 88.8 %. The efficacy rates were 87.3%, 88.4% and 90.3 %for periodo-ntitis, pericoronitis and osteitis of jaw, respectively. The overall efficacy rate assessed by the principal investigators was 86.5%.<BR>2) The efficacy rates of 200 mg group and 400 mg group as judged by the committee were 87.1% and 91.2%, respectively.<BR>3) On the bacteriological effect, eradication rate judged by the committee was 90.3 %. The MIC<SUB>80</SUB> against 77 strains of Oral Streptococci was 0.39 μg/ ml.<BR>4) Side effects were noted in 3 patients (1.4%) out of 221 patients and the symptoms were diarrhea, gastralgia and dizziness. These symptoms were mild. Abnormal changes in laboratory tests were found in 12 patients (7.8 %) out of 154 patients examined. Major items were elevation of transaminase and increase of eosinophil.<BR>From the above results, CPDX-PR was considered to be useful in the treatment of odontogenic infections. As for the recommended dose, a daily dose of 200 mg proved to exert the expected effect.
- 日本歯科薬物療法学会の論文
日本歯科薬物療法学会 | 論文
- カンジダのバイオフィルム産生性に対する抗真菌薬の効果
- 当院における全身麻酔下手術中に使用された抗菌薬の15年間(1992-2006年)の推移
- 「顎骨骨髄炎に対する抗菌薬の効果判定基準」の解析結果
- 植物精油の口腔微生物に対する抗菌性およびバイオフィルム形成抑制効果の検討
- ニフェジピン歯肉増殖症患者の線維芽細胞に対する18α-グリチルレチン酸のアポトーシス誘導効果